Skip Nav Destination
ERRATUM|
March 30, 2023
Heiblig M, Ferrada MA, Koster MT, et al. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood. 2022;140(8):927-931.
Blood (2023) 141 (13): 1647.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal